| 序号 |
标题 |
次数 |
作者 |
发布时间 |
| 89146 |
DOTA-五聚乙二醇-C4-二苯并环辛炔 DOTA-PEG5-C4-DBCO |
139 |
zcy |
2024-11-29 |
| 89147 |
1539292-60-8,APN-C3-NH-Boc |
147 |
kx |
2024-11-29 |
| 89148 |
DOTA-cyclo(Arg-Gly-Asp-DPhe-Lys) |
129 |
wyh |
2024-11-29 |
| 89149 |
DOTA-TMTP1的性质与应用 |
125 |
wyh |
2024-11-29 |
| 89150 |
DOTA-三聚乙二醇-叠氮(盐酸盐) DOTA-PEG3-azide(HCl) 1428146-79-5 |
123 |
zcy |
2024-11-29 |
| 89151 |
7-R-7-磷杂降冰片二烯M(CO)5(M=Mo,W)配合物 |
265 |
h |
2024-11-29 |
| 89152 |
DOTA-cyclo(RGDfK) ;DOTA-RGD |
184 |
wyh |
2024-11-29 |
| 89153 |
2376146-48-2,ZN-c3 |
146 |
kx |
2024-11-29 |
| 89154 |
Mem-Tz-Rh 四嗪与罗丹明结构连接溶酶体靶向探针 |
217 |
WYQ |
2024-11-29 |
| 89155 |
Mito-Tz-BDP Bodipy与四嗪共轭连接线粒体靶向探针 |
254 |
WYQ |
2024-11-29 |
| 89156 |
3-三氟甲基-6-硝基胍基[1,2,4]三唑并[4,3-b][1,2,4,5]四嗪化合物 |
157 |
WYQ |
2024-11-29 |
| 89157 |
DOTA-「Tyr3」-Octreotide , DOTA-(酪氨酸3)-奥曲肽 |
144 |
wyh |
2024-11-29 |
| 89158 |
1,4-二吡唑基-2,3,5,6-四嗪构筑的金属有机框架 |
158 |
WYQ |
2024-11-29 |
| 89159 |
1,4-二-(吡唑基)-2,3,5,6-四嗪修饰三氟甲基磺酸锌[Zn(bptz)2]n |
226 |
WYQ |
2024-11-29 |
| 89160 |
3,6-二(4-吡啶基)-1,2,4,5-四嗪 |
134 |
WYQ |
2024-11-29 |
| 89161 |
DOTA-PEG4-MeTz DOTA-PEG4-甲基四嗪 甲基四嗪聚乙二醇大环化合物 |
182 |
zcy |
2024-11-29 |
| 89162 |
5966-29-0;N-棕榈酰-D-赤型-鞘氨醇;C16 Dihydroceramide (d18:0/16:0) |
610 |
kx |
2024-11-29 |
| 89163 |
p-SCN-Bn-DOTA ;2-[(4-异硫氰基苯基)甲基]-1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸 |
155 |
wyh |
2024-11-29 |
| 89164 |
DOTA-Suc-Lys-(FAPI-04)2 3029114-60-8 DOTA-琥珀酰基-赖氨酸-(FAPI-04)2 |
146 |
zcy |
2024-11-29 |
| 89165 |
913528-04-8 , DOTAM-mono-acid-CSDN |
117 |
wyh |
2024-11-29 |
| 89166 |
降冰片烯单体[5-降冰片烯-2-亚甲氧基-4-己氧基联苯(PhHN)] |
200 |
h |
2024-11-29 |
| 89167 |
Tm-DOTA , DOTA大环化合物 |
128 |
wyh |
2024-11-29 |
| 89168 |
四嗪基UIO-66金属有机骨架 |
323 |
WYQ |
2024-11-29 |
| 89169 |
DOTA-D-PHE-CYS-TYR-D-TRP-LYS-THR-CYS-THR-OL (DISULFIDE BRIDGE: 2-7) 定制 |
148 |
zcy |
2024-11-29 |
| 89170 |
四嗪功能基团修饰寡聚(p-苯撑乙炔)分子 |
183 |
WYQ |
2024-11-29 |
| 89171 |
icariside C3,CAS号:108906-48-5 |
185 |
zyl |
2024-11-29 |
| 89172 |
1,2,4,5-四嗪-3,5-双(1H-1,2,4-三唑-3-硝胺基) |
167 |
WYQ |
2024-11-29 |
| 89173 |
DOTA-tris(acid)-amido-dPEG®11-Maleimide;DOTA-聚乙二醇(dPEG)间隔基-马来酰亚胺 |
146 |
zcy |
2024-11-29 |
| 89174 |
3-三氟甲基-6-氨基[1,2,4]三唑并[4,3-b][1,2,4,5]四嗪类含能化合物 |
131 |
WYQ |
2024-11-29 |
| 89175 |
DOTA-(Tyr3)-Octreotate ,DOTA-3-酪氨酰基-奥曲肽 |
104 |
wyh |
2024-11-29 |
| 89176 |
N-(3-(三氟甲基)-[1,2,4]三唑并[4,3-b][1,2,4,5]四嗪)硝酸酰胺 |
179 |
WYQ |
2024-11-29 |
| 89177 |
TCO-C3-PEG3-C3-amine,cas:2028288-77-7,反式环辛烯-C3-三聚乙二醇-C3-氨基 |
155 |
zyl |
2024-11-29 |
| 89178 |
Maleimide-DOTA-GA 马来酰亚胺-DOTA-镓 大环配体化合物 |
220 |
zcy |
2024-11-29 |
| 89179 |
Mem-Tz-Rh 四嗪与罗丹明结构连接溶酶体靶向探针 |
255 |
WYQ |
2024-11-29 |
| 89180 |
Mito-Tz-BDP Bodipy与四嗪共轭连接线粒体靶向探针 |
207 |
WYQ |
2024-11-29 |
| 89181 |
DOTA标记的双c(RGDfK)环肽 |
168 |
wyh |
2024-11-29 |
| 89182 |
3-三氟甲基-6-硝基胍基 [1,2,4]三唑并[4,3-b][1,2,4,5]四嗪化合物 |
182 |
WYQ |
2024-11-29 |
| 89183 |
DOTA-Ubiquicidin (29-41) acetate 基于NOTADOTA定制和偶联 |
153 |
zcy |
2024-11-29 |
| 89184 |
N-(3-(三氟甲基)-[1,2,4]三唑并[4,3-b] [1,2,4,5]四嗪)硝酸酰胺 |
177 |
WYQ |
2024-11-29 |
| 89185 |
C16-02:0 PC;CAS号:74389-68-7 |
151 |
zyl |
2024-11-29 |
| 89186 |
6 -氨-3-(三氟甲基)-[1,2,4]三唑[4,3-b] [1,2,4,5]四嗪 |
134 |
WYQ |
2024-11-29 |
| 89187 |
Cuprate(2-)-64Cu, [N-[2-[4,10-bis[(carboxy-κO)methyl]-7-(carboxymethyl)-1,4,7,10-tetraazacyclododec-1 定制 |
154 |
zcy |
2024-11-29 |
| 89188 |
1006711-90-5 ,DOTA-MAL , DOTA-马来酰亚胺 |
250 |
wyh |
2024-11-29 |
| 89189 |
6 -(3,5-二甲基吡唑)-3-(三氟甲基)-[1,2,4]三唑并[4,3-b] [1,2,4,5]四嗪 |
155 |
WYQ |
2024-11-29 |
| 89190 |
N-stearoyl-D-erythro-sphingosine (C17 base), powder;CAS号:123065-42-9 |
156 |
zyl |
2024-11-29 |